Peer-reviewed veterinary case report
Domperidone effects on inflammation markers in dogs with leishmaniasis
By Paltrinieri, Saverio et al.·Published in Veterinary clinical pathology·2020·Department of Veterinary Medicine, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Influence of domperidone supplementation on short-term changes in C-reactive protein and paraoxonase-1 in dogs with leishmaniasis undergoing meglumine antimoniate and allopurinol therapy.
- Species:
- dog
Plain-English summary
A group of dogs with mild leishmaniasis (a disease caused by parasites) were treated with a common medication and an additional supplement called domperidone to see if it would help their recovery. While the dogs receiving domperidone showed a temporary increase in a protein linked to inflammation (C-reactive protein) shortly after starting treatment, all of them had normal levels by three weeks. This suggests that the domperidone did not worsen their condition, and it may help improve their overall response to treatment.
People also search for: dog leishmaniasis treatment · domperidone for dogs · C-reactive protein in dogs
Abstract
BACKGROUND: C-reactive protein (CRP) and paraoxonase 1 (PON1) might increase and decrease in canine leishmaniasis (CanL), , and both can rapidly normalize after therapy. Recently, supplementation of domperidone with conventional therapy , increasing the activity of cells involved in acute phase responses in vitro. This combined therapy has been recommended to treat mild forms of CanL; however, no studies have investigated the effects of domperidone supplementation on early CRP or PON1 changes in dogs with CanL. OBJECTIVES: The aim of this study was to evaluate whether domperidone, added to conventional treatments, modifies CRP concentration and PON1 activity kinetics in CanL dogs responsive to conventional therapy. METHODS: Serum CRP concentrations and PON1 activities were measured in dogs with mild CanL before (t-0) and 3 (t-1), 7 (t-2), 14 (t-3), and 21 (t-4) days after treatment with N-methylglucamine antimoniate and allopurinol alone (n = 18) or combined with domperidone (n = 18). RESULTS: C-reactive protein concentrations increased at t-1 in the domperidone group, especially when the CRP concentration at t-0 was normal. However, the concentrations normalized at t-4 in 18/18 dogs compared with 14/18 dogs not receiving domperidone. The median PON1 activity decreased at t-1 in the domperidone group, and this decrease was more significant in dogs with normal PON1 activity at t-0. CONCLUSIONS: Based on these results, transient increases in CRP concentrations or decreases in PON1 activities after domperidone administration should not be erroneously interpreted as signs of a worsening disease process.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33341970/